- Home
- NRXP vs CGO Comparison
NRXP vs CGO Comparison
Compare NRXP & CGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXP | CGO |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 129.6M |
| IPO Year | 2017 | 2004 |
Fundamental Metrics
Financial Performance| Metric | NRXP | CGO |
|---|---|---|
| Price | $3.24 | $13.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $38.25 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 27.5K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.25% |
| EPS Growth | ★ 69.70 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,225,000.00 | N/A |
| Revenue This Year | $2,547.84 | N/A |
| Revenue Next Year | $1,591.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $10.71 |
| 52 Week High | $5.06 | $14.20 |
Technical Indicators
Market Signals| Indicator | NRXP | CGO |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 56.63 |
| Support Level | $2.88 | $12.97 |
| Resistance Level | $3.33 | $13.88 |
| Average True Range (ATR) | 0.32 | 0.30 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 30.83 | 87.34 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.